TP53 and neoplasm: In Gambia, a country with high exposure to AFB-1, the TP53 R249S mutation has been identified in 35% of HCC biopsies and in 42% of plasma samples from HCC patients with a concordance of 88.5% between tumour tissues and matched plasma [60].